Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project
The TAT for molecular-biomarker testing is an ongoing and complex challenge for healthcare systems worldwide. This QI project is a step towards addressing province-wide reduction in wait times for molecular-biomarker testing results in BC. We continue to explore further ideas to improve workflow metrics and patient care among patients with advanced NSCLC.
Authors
- Deepu Alex (ORCID: https://orcid.org/0000-0001-6136-296X)
- Stephen Yip (ORCID: https://orcid.org/0000-0002-8514-9861)
- Tawimas Shaipanich (ORCID: https://orcid.org/0000-0001-5551-0073)
- Hannah Carolan
- Barbara Melosky (ORCID: https://orcid.org/0000-0003-2865-659X)
- Kelly Zibrik
- Jane C. Sun
- Diana N. Ionescu (ORCID: https://orcid.org/0000-0001-5112-1310)
- Sarah Yeo (ORCID: https://orcid.org/0000-0003-1705-0429)
- Ying Wang (ORCID: https://orcid.org/0000-0002-2571-9367)
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Spinal Cord Injury BC (CA)
- BC Cancer Foundation (CA)
Publication Details
- Journal
- BMJ Open Quality
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjoq-2024-003001
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca Canada